FOLFIRI with or without celecoxib in advanced colorectal cancer: A randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

Annals of Oncology

Volumn 17, Issue SUPPL. 7, 2006, Pages

  Maiello, E ^a,b   Giuliani, F ^a   Gebbia, V ^c   Di Renzo, N ^d   Pezzella, G ^e   Romito, S ^f   Mallamaci, R ^a   Lopez, M ^g   Colucci, G ^g  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Oncologic Center   (Italy)

^e Ospedale Nord   (Italy)

^f Cardarelli Hospital   (Italy)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Celecoxib; Colorectal cancer; Fluorouracil; Folinic acid; Irinotecan

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; CELECOXIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OXALIPLATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHOLINERGIC SYNDROME; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; ORAL REHYDRATION THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 33745634877     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl952     Document Type: Article

References (19)

1. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000; 355: 1041-1047.
2. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
3. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI vs FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). J Clin Oncol 2005; 23: 4866-4875.
4. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916.
5. Dannenberg AJ, Aitorki NK, Boyle JO et al. Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2:544-551.
6. Yamauchi T, Watanabe M, Kubota T et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002; 45: 98-103.
7. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rew Cancer 2001; 1: 11-21.
8. Arber N, Dubois RN. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenteral Rep 1999; 1: 441-448.
9. Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003; 90: 1055-1057.
10. Thun W, Henley SJ, Patrono G: Non-steroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94:252-266.
11. Therrasse P, Arbuck SG, Eisenhauer EA et al. New guidelines toevaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
12. Blanke CD, Benson AB, Dragovich T et al. A phase II trial of celecoxib, irinotecan, 5-fluorourail, and leucovorin in patients with unresectable or metastatic colorectal cancer: Proc. Am Soc Clin Oncol 2002; 21: 505 (Abstr).
13. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
14. Pan C, Loehrer P, Juliar B et al. A phase II trial of irinotecan, 5-fluorouracil, leucovorin (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer: A Hoosier Oncology Group study. Proc Am Soc Clin Oncol 2003; 22:1347 (abst).
15. Lin E, Morris JS, Ayers GD. effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 2002; 16 (Suppl 14): 31-37.
16. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer. A phase II study. Int J Cancer 2003; 105: 868-872.
17. Gasparini G, Gattuso D, Morabito A et al. Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. The Oncologist 2005; 10: 710-717.
18. Maiello E, Gebbia V, Giuliani F et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomized phase II study of the Southern Italy Oncology group. Ann Oncol 2000; 11: 1045-1051.
19. Solomon SD, McMurray JJV, Pfeifer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl Med J 2005; 353: 1071-1080.